DiaRem2: Incorporating Duration of Diabetes to Improve Prediction of Diabetes Remission After Metabolic Surgery

Overview

Journal Surg Obes Relat Dis

Publisher Elsevier

Specialty Endocrinology

Date 2019 Jan 29

PMID 30686670

Citations 6

Authors

Christopher D Still

Peter Benotti

Tooraj Mirshahi

Adam Cook

G Craig Wood

Affiliations

Soon will be listed here.

Abstract

Background: DiaRem is a validated tool for predicting the likelihood of type 2 diabetes (T2D) remission after Roux-en-Y gastric bypass (RYGB) surgery.

Objectives: The objective of this study was to determine if the addition of duration of T2D to DiaRem improves its ability to discriminate between patients with or without T2D remission and/or to reclassify presurgery patients into accurate risk groups.

Setting: Academic Medical Center.

Methods: This study included patients consented into a prospective registry of Roux-en-Y gastric bypass between July 2009 and November 2015 with known duration of T2D (n = 307). Electronic health record-derived duration of T2D was compared with patient reported duration of T2D in a subset of patients (n = 48). DiaRem2 was created using clinical variables from DiaRem and duration of T2D. Area under the curve and the net reclassification index were used to assess increased performance of DiaRem2.

Results: Self-reported duration of T2D was highly concordant with electronic health record-derived T2D duration (96% agreement). Early T2D remission occurred in 44% of patients. DiaRem2 included age, hemoglobin A1C, insulin medication use, and duration of T2D. DiaRem2 had a higher area under the curve than DiaRem (.876 versus .850, P = .026), reduced the number of remission risk groups from 5 down to 3, and reclassified patients from intermediate to either high or low remission groups (net reclassification index, P < .0001).

Conclusions: DiaRem2 simplifies and improves the accuracy of assessing probability of T2M remission after Roux-en-Y gastric bypass. Self-reported duration of T2D is an acceptable surrogate for T2D duration derived from clinical data.

Citing Articles

Mexican Clinical Practice Guidelines for Adult Overweight and Obesity Management.

Chavez-Manzanera E, Vera-Zertuche J, Kaufer-Horwitz M, Vazquez-Velazquez V, Flores-Lazaro J, Mireles-Zavala L Curr Obes Rep. 2024; 13(4):643-666.

PMID: 39356455 PMC: 11522083. DOI: 10.1007/s13679-024-00585-w.

A multi-center study on glucometabolic response to bariatric surgery for different subtypes of obesity.

Liu Y, Sheng C, Feng W, Sun F, Zhang J, Chen Y Front Endocrinol (Lausanne). 2022; 13:989202.

PMID: 36407309 PMC: 9669340. DOI: 10.3389/fendo.2022.989202.

Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus.

Kim J, Kwon H Diabetes Metab J. 2022; 46(2):165-180.

PMID: 35385632 PMC: 8987695. DOI: 10.4093/dmj.2021.0377.

C-peptide level as predictor of type 2 diabetes remission and body composition changes in non-diabetic and diabetic patients after Roux-en-Y gastric bypass.

de Cleva R, Kawamoto F, Borges G, Caproni P, Cassenote A, Santo M Clinics (Sao Paulo). 2021; 76:e2906.

PMID: 34378729 PMC: 8311643. DOI: 10.6061/clinics/2021/e2906.

Diabetes remission after bariatric surgery.

Chumakova-Orin M, Vanetta C, Moris D, Guerron A World J Diabetes. 2021; 12(7):1093-1101.

PMID: 34326957 PMC: 8311476. DOI: 10.4239/wjd.v12.i7.1093.

References

Buse J, Caprio S, Cefalu W, Ceriello A, Del Prato S, Inzucchi S . How do we define cure of diabetes?. Diabetes Care. 2009; 32(11):2133-5. PMC: 2768219. DOI: 10.2337/dc09-9036. View

Hassan M, Curley S, Li D, Kaseb A, Davila M, Abdalla E . Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010; 116(8):1938-46. PMC: 4123320. DOI: 10.1002/cncr.24982. View

. Standards of medical care in diabetes--2012. Diabetes Care. 2011; 35 Suppl 1:S11-63. PMC: 3632172. DOI: 10.2337/dc12-s011. View

Wood G, Chu X, Manney C, Strodel W, Petrick A, Gabrielsen J . An electronic health record-enabled obesity database. BMC Med Inform Decis Mak. 2012; 12:45. PMC: 3508953. DOI: 10.1186/1472-6947-12-45. View

Still C, Wood G, Benotti P, Petrick A, Gabrielsen J, Strodel W . Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol. 2014; 2(1):38-45. PMC: 3932625. DOI: 10.1016/S2213-8587(13)70070-6. View

Aminian A, Brethauer S, Kashyap S, Kirwan J, Schauer P . DiaRem score: external validation. Lancet Diabetes Endocrinol. 2014; 2(1):12-3. DOI: 10.1016/S2213-8587(13)70202-X. View

Cotillard A, Poitou C, Duchateau-Nguyen G, Aron-Wisnewsky J, Bouillot J, Schindler T . Type 2 Diabetes Remission After Gastric Bypass: What Is the Best Prediction Tool for Clinicians?. Obes Surg. 2014; 25(7):1128-32. DOI: 10.1007/s11695-014-1511-8. View

Sampaio-Neto J, Nassif L, Branco-Filho A, Bolfarini L, Loro L, de Souza M . EXTERNAL VALIDATION OF THE DIAREM SCORE AS REMISSION PREDICTOR OF DIABETES MELLITUS TYPE 2 IN OBESE PATIENTS UNDERGOING ROUX-EN-Y GASTRIC BYPASS. Arq Bras Cir Dig. 2015; 28 Suppl 1:19-22. PMC: 4795300. DOI: 10.1590/S0102-6720201500S100007. View

Panunzi S, Carlsson L, De Gaetano A, Peltonen M, Rice T, Sjostrom L . Determinants of Diabetes Remission and Glycemic Control After Bariatric Surgery. Diabetes Care. 2015; 39(1):166-74. DOI: 10.2337/dc15-0575. View

10.

Lovaas K, Cooper J, Sandberg S, Roraas T, Thue G . Feasibility of using self-reported patient data in a national diabetes register. BMC Health Serv Res. 2015; 15:553. PMC: 4678468. DOI: 10.1186/s12913-015-1226-0. View

11.

Lee W, Chong K, Chen S, Zachariah J, Ser K, Lee Y . Preoperative Prediction of Type 2 Diabetes Remission After Gastric Bypass Surgery: a Comparison of DiaRem Scores and ABCD Scores. Obes Surg. 2016; 26(10):2418-24. DOI: 10.1007/s11695-016-2120-5. View

12.

Mehaffey J, Mullen M, Mehaffey R, Turrentine F, Malin S, Kirby J . Type 2 diabetes remission following gastric bypass: does diarem stand the test of time?. Surg Endosc. 2016; 31(2):538-542. PMC: 5107360. DOI: 10.1007/s00464-016-4964-0. View

13.

Purnell J, Selzer F, Wahed A, Pender J, Pories W, Pomp A . Type 2 Diabetes Remission Rates After Laparoscopic Gastric Bypass and Gastric Banding: Results of the Longitudinal Assessment of Bariatric Surgery Study. Diabetes Care. 2016; 39(7):1101-7. PMC: 4915561. DOI: 10.2337/dc15-2138. View

14.

Tharakan G, Scott R, Szepietowski O, Miras A, Blakemore A, Purkayastha S . Limitations of the DiaRem Score in Predicting Remission of Diabetes Following Roux-En-Y Gastric Bypass (RYGB) in an ethnically Diverse Population from a Single Institution in the UK. Obes Surg. 2016; 27(3):782-786. PMC: 5306254. DOI: 10.1007/s11695-016-2368-9. View

15.

Honarmand K, Chetty K, Vanniyasingam T, Anvari M, Chetty V . Type 2 diabetes remission rates 1-year post-Roux-en-Y gastric bypass and validation of the DiaRem score: the Ontario Bariatric Network experience. Clin Obes. 2017; 7(3):176-182. DOI: 10.1111/cob.12189. View

16.

Wood G, Horwitz D, Still C, Mirshahi T, Benotti P, Parikh M . Performance of the DiaRem Score for Predicting Diabetes Remission in Two Health Systems Following Bariatric Surgery Procedures in Hispanic and non-Hispanic White Patients. Obes Surg. 2017; 28(1):61-68. PMC: 5736407. DOI: 10.1007/s11695-017-2799-y. View

17.

Aron-Wisnewsky J, Sokolovska N, Liu Y, Comaneshter D, Vinker S, Pecht T . The advanced-DiaRem score improves prediction of diabetes remission 1 year post-Roux-en-Y gastric bypass. Diabetologia. 2017; 60(10):1892-1902. DOI: 10.1007/s00125-017-4371-7. View